An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers

NCT06025318 | Completed Phase 1 FDA Drug

• 1 other identifier: VRS-23-001
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label, balanced, randomized, two-period, crossover, single dose study to compare the relative bioavailability in normal healthy, adult, human subjects under Fed and Fasting conditions. Subjects will receive a single oral dose of probenecid oral suspension (100 mg/mL) under fed and fasted conditions.

Conditions

Relative Bioavailability

Outcome Measures

Primary Outcomes (2)

• To assess food effect on PanCytoVir™ in healthy, adult, human subjects as assessed by Cmax

  The drug concentration in plasma assessed by Cmax

  7 days

• To assess food effect on PanCytoVir™ in healthy, adult, human subjects as assessed by AUC

  The drug concentration in plasma assessed by AUC

  7 days

Secondary Outcomes (1)

• the Incidence rates of AEs, TEAEs and Serious Adverse Events (SAEs)

  7 days

Study Arms (2)

PanCytoVir™ 1000 mg fasted

EXPERIMENTAL

Single oral dose of PanCytoVir™ 1000 mg (100 mg/mL suspension) following an overnight fast

Drug: PanCytoVir™

PanCytoVir™ 1000 mg fed

EXPERIMENTAL

Single oral dose of PanCytoVir™ 1000 mg (100 mg/mL suspension) following a standard, high-fat, high-calorie breakfast

Drug: PanCytoVir™

Interventions

PanCytoVir™ DRUG

PanCytoVir™ 100 mg/mL oral suspension

PanCytoVir™ 1000 mg fasted; PanCytoVir™ 1000 mg fed

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Normal healthy adult human subjects.
• Subjects who are willing to participate and give informed consent
• Subjects who are ≥ 18 years of age to ≤ 45 years of age and have a Body Mass Index between ≥18.5 to ≤ 30.0 kg/m2 extremes included, with weight of at least 50 kg.
• Subjects with normal findings as determined by baseline history, physical examination and vital sign examination (blood pressure, pulse rate, respiration rate and body temperature).
• Subjects with clinically acceptable findings as determined by haemogram, biochemistry, urine analysis, 12 lead ECG and chest X-ray.
• Willingness to follow the protocol requirements especially abstaining from xanthine containing food or beverages (chocolates, tea, coffee or cola drinks) or grapefruit juice, any alcoholic products, the use of cigarettes and the use of tobacco products for 72.00 hours prior to dosing until after the last blood sample collection in each study period and adherence to food, fluid and posture restrictions.
• No history of significant alcoholism.
• Subject who have an estimated glomerular filtration rate (eGFR) value is \>60ml/min.
• Found negative in Alcohol test.
• Found negative in urine test for drug abuse \[Benzodiazepines, Barbiturates, Morphine, Cocaine, Amphetamines and Tetrahydrocannabinol (THC)\].
• Non-smokers, ex-smokers and moderate smokers will be included. "Moderate smokers are defined as someone smoking 10 cigarettes or less per day, ex-smokers are someone who completely stopped smoking for at least 3 months."

You may not qualify if:

• History of allergic responses or hypersensitivity to Probenecid or other related drugs, or any of its ingredients.
• Requiring medication for any ailment having enzyme-modifying activity in the previous 21 days, prior to dosing day.
• Subjects who have taken prescription medications or over-the-counter products (including vitamins and minerals) within 14 days prior to administration of study drug
• Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.
• History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, haematological, gastrointestinal, endocrine, immunological or psychiatric diseases.
• Participation in a clinical drug study or bioequivalence study 90 days prior to period I dosing of the present study.
• History of malignancy or other serious diseases.
• Blood donation 90 days prior to period I dosing of the present study.
• Subjects with positive HIV tests, HBsAg or Hepatitis-C tests.
• History of problem in swallowing tablets/capsules/ Suspension.
• Any contraindication to blood sampling.
• Female subjects found positive serum (β) Beta- hCG (Human Chorionic Gonadotropin) test.
• Lactating women (currently breast feeding).
• Female subjects not confirming to using birth control measures, from the date of screening until the completion of the study. Abstinence, barrier methods (condom, diaphragm, etc.) are acceptable.
• Use of hormonal contraceptives either oral or implants.

Sponsors & Collaborators

• TrippBio, Inc.: lead

Study Sites (1)

Vayam Research Solutions Limited

Gujarat, India, India

Location

Study Officials

• David E Martin, PharmD

  TrippBio, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 24, 2023
• First Posted: September 6, 2023
• Study Start: September 1, 2024
• Primary Completion: September 30, 2024
• Study Completion: October 15, 2024
• Last Updated: November 21, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

IN (1)